The role of the gut microbiota in Parkinson’s disease

Close metadata

ABTRACT

Recently, an important role in the development of Parkinson’s disease (PD) is assigned to the gastrointestinal tract and the enteral nervous system. In particular, the pathological process of PD begins in the gastrointestinal tract decades before progressing to the central nervous system. The microbiota-gut-brain axis is a two-way connecting system between the central nervous system and the gastrointestinal tract. The pathogenesis of PD can be caused or aggravated by changes in the gastrointestinal microbiota composition. It is shown that patients with PD have changes in the intestinal microbiota. A better understanding of gut-brain interactions and the role of the gut microbiota in regulation the immune response can both bring new knowledge about the pathological progression of PD, and contribute to the development of new diagnostic and therapeutic approaches.

Keywords:

Parkinson’s disease

pathogenesis

gut microbiota

enteric nervous system

microbiota—gut—brain axis

Authors:

Verugina N.I.

Russian Medical Academy of Continuous Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

SPIN RSCI: 5342-1373
Scopus AuthorID: 57147160800
ORCID: 0000-0003-3872-5923

Lyashenko E.A.

Russian Medical Academy of Continuous Professional Education

Received:

02.09.2021

Accepted:

08.09.2021

List of references:

Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2009;24(6):793-800. https://doi.org/10.1002/mds.22172
Chen H, Zhao EJ, Zhang W. et al. Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis. Transl Neurodegener. 2015;4(1):1. https://doi.org/10.1186/2047-9158-4-1
Fasano A, Visanji NP, Liu L. et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625-639. https://doi.org/10.1016/S1474-4422(15)00007-1
Dutkiewicz J, Szlufik S, Nieciecki M. et al. Intestine dysfunction in Parkinson’s disease. J Neural Transm (Vienna). 2015;122:1659-1661. https://doi.org/10.1007/s00702-015-1442-0
Abbott RD, Petrovitch H, White LR. et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57:456-462.
Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson’s disease. Am J Epidemiol. 2011;174:546-551. https://doi.org/10.1093/aje/kwr119
Adams-Carr KL, Bestwick JP, Shribman S. et al. Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;87:710-716. https://doi.org/10.1136/jnnp-2015-311680
Berg D, Postuma RB, Adler CH. et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2015;30(12):1600-1611. https://doi.org/10.1002/mds.26431
Sánchez-Ferro Á, Rábano A, Catalán MJ. et al. In vivo gastric detection of α-synuclein inclusions in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2015;30(4):517-524. https://doi.org/10.1002/mds.25988
Tan AH, Mahadeva S, Thalha AM. et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(5):535-540. https://doi.org/10.1016/j.parkreldis.2014.02.019
Gasbarrini A, Lauritano EC, Gabrielli M. et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis Basel Switz. 2007;25(3):237-240. https://doi.org/10.1159/000103892
Chen WC, Quigley EM. Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: opening up a new therapeutic horizon! Indian J Med Res. 2014;140(5):582-584.
Fasano A, Bove F, Gabrielli M. et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord. 2013;28:1241-1249. https://doi.org/10.1002/mds.25522
Lin J-C, Lin C-S, Hsu C-W. et al. Association between Parkinson’s disease and inflammatory bowel disease: a nationwide Taiwanese retrospective cohort study. Inflamm Bowel Dis. 2016;22(5):1049-1055. https://doi.org/10.1097/MIB.0000000000000735
Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144:36-49. https://doi.org/10.1053/j.gastro.2012.10.003
Mertsalmi H, Aho E, Pereira A. et al. More than constipation—bowel symptoms in Parkinson’s disease and their connection to gut microbiota. European journal of neurology. 2017;24(11):1375-1383. https://doi.org/10.1111/ene.13398
Lai SW, Liao KF, Lin CL, Sung FC. Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan. Eur J Epidemiol. 2014;29:57-62. https://doi.org/10.1007/s10654-014-9878-3
Pan-Montojo F, Schwarz M, Winkler C. et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep. 2012;2:898. https://doi.org/10.1038/srep00898
Cryan JF, O’Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011;23:187-192. https://doi.org/10.1111/j.1365-2982.2010.01664.x
Mayer EA, Tillisch K, Bradesi S. Review article: modulation of the brain — gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther. 2006;24:919-933. https://doi.org/10.1111/j.1365-2036.2006.03078.x
Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol. 2011;2:94. https://doi.org/10.3389/fphys.2011.00094
O’Mahony SM, Hyland NP, Dinan TG, Cryan JF. Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl). 2011;214:71-88. https://doi.org/10.1007/s00213-010-2010-9
Quigley EM, Monsour HP. The gut microbiota and nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:262-269. https://doi.org/10.1055/s-0035-1562946
Thakur AK, Shakya A, Husain GM. et al. Gut-microbiota and mental health: current and future perspectives. J Pharmacol Clin Toxicol. 2014;2:1016.
Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6(5):306-314. https://doi.org/10.1038/nrgastro.2009.35
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701-712. https://doi.org/10.1038/nrn3346
Perez-Pardo P, Hartog M, Garssen J, Kraneveld D. Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson’s Disease. Current Behavioral Neuroscience Reports. 2017;4(4):361-368. https://doi.org/10.1007/s40473-017-0129-2
Blekhman R, Goodrich JK, Huang K, et al. Host genetic variation impacts microbiome composition across human body sites. Genome Biol. 2015;16:191. https://doi.org/10.1186/s13059-015-0759-1
Bäckhed F, Roswall J, Peng Y. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;17:690-703. https://doi.org/10.1016/j.chom.2015.04.004
Dietert J, Dietert R. The sum of our parts. Scientist. 2015;29:44-49.
Van Opstal EJ, Bordenstein SR. Rethinking heritability of the microbiome. Science. 2015;349:1172-1173. https://doi.org/10.1126/science.aab3958
Zeevi D, Korem T, Zmora N. et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079-1094. https://doi.org/10.1016/j.cell.2015.11.001
Friedland RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimers Dis. 2015;45:349-362. https://doi.org/10.3233/JAD-142841
Unger MM, Spiegel J, Dillmann K-U, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66-72. https://doi.org/10.1016/j.parkreldis.2016.08.019
Keshavarzian A, Green SJ, Engen P. et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2015;30(10):1351-1360. https://doi.org/10.1002/mds.26307
Eisenhofer G, Aneman A, Friberg P. et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab. 1997;82:3864-3871. https://doi.org/10.1210/jcem.82.11.4339
Forsyth CB, Shannon KM, Kordower JH. et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One. 2011;6(12):e28032. https://doi.org/10.1371/journal.pone.0028032
Scheperjans F, Aho V, Pereira PAB. et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord Off J Mov Disord Soc. 2015;30(3):350-358. https://doi.org/10.1002/mds.26069
Andrews ZB, Erion D, Beiler R. et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci. 2009;29(45):14057-14065. https://doi.org/10.1523/JNEUROSCI.3890-09.2009
Andrews ZB. The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci. 2011;34:31-40. https://doi.org/10.1016/j.tins.2010.10.001
Çamci G, Oğuz S. Association between Parkinson’s disease and helicobacter pylori. J Clin Neurol. 2016;12:47-50. https://doi.org/10.3988/jcn.2016.12.2.147
Brenner SR. Blue-green algae or cyanobacteria in the intestinal microflora may produce neurotoxins such as Beta-N-Methylamino-L-Alanine (BMAA) which may be related to development of Amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson-dementia-complex in humans and equine motor neuron disease in horses. Med Hypotheses. 2013;80:103. https://doi.org/10.1016/j.mehy.2012.10.010
Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev MMBR. 1998;62(2):379-433.
Forsythe P, Kunze WA. Voices from within: gut microbes and the CNS. Cell Mol Life Sci CMLS. 2013;70(1):55-69. https://doi.org/10.1007/s00018-012-1028-z
Hsu YT, Liao CC, Chang SN. et al. Increased risk of depression in patients with Parkinson disease: a nationwide cohort study. Am J Geriatr Psychiatry. 2015;23:934-940. https://doi.org/10.1016/j.jagp.2014.10.011
Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008;29:117-124.
Sampson TR, Debelius JW, Thron T. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167(6): Curr Behav Neurosci Rep. 2017;4:361-368, 1469—1480.e12. https://doi.org/10.1016/j.cell.2016.11.018
Lyte M. Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. PLoS Pathog. 2013;9(11):e1003726. https://doi.org/10.1371/journal.ppat.1003726
Devos D, Lebouvier T, Lardeux B. et al. Colonic inflammation in Parkinson’s disease. Neurobiol Dis. 2013;50(1):42-48. https://doi.org/10.1016/j.nbd.2012.09.007
Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382-397. https://doi.org/10.1016/S1474-4422(09)70062-6
Helander HF, Fändriks L. Surface area of the digestive tract—revisited. Scand J Gastroenterol. 2014;49(6):681-689. https://doi.org/10.3109/00365521.2014.898326
Lema Tomé CM, Tyson T, Rey NL, et al. Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease — is there a link? Mol Neurobiol. 2013;47(2):561-574. https://doi.org/10.1007/s12035-012-8267-8
Guan J, Pavlovic D, Dalkie N. et al. Vascular degeneration in Parkinson’s disease. Brain Pathol Zurich Switz. 2013;23(2):154-164. https://doi.org/10.1111/j.1750-3639.2012.00628.x
Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm Vienna Austria. 1996. 2003;110(5):517-536. https://doi.org/10.1007/s00702-002-0808-2
Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33(6):599-614. https://doi.org/10.1111/j.1365-2990.2007.00874.x
Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease-the gut-brain axis and environmental factors. Nat Rev Neurol. 2015;11(11):625-636. https://doi.org/10.1038/nrneurol.2015.197

Close metadata